SQLite Web: event_store.db

Update row 39561 in events

seq

Primary key. INTEGER

id

TEXT NOT NULL

kind

TEXT NOT NULL

ts

TEXT NOT NULL

actor

TEXT

subject_entity_ids

TEXT

payload

{"created_at":"2026-04-14T02:04:49.876253+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:a1ef5cc59ac1f1fc","evidence_event_ids":["evt_4d6f93f5e6c4"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1806310/0001665124-26-000011.txt","as_of":"2026-04-14T02:04:49.876253+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1806310/0001665124-26-000011.txt","company":"Taysha Gene Therapies, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1806310/0001665124-26-000011.txt","article_chars":2517,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_c81dec68c40397ca","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1806310/0001665124-26-000011.txt","content_type":"text/plain","enriched_at":"2026-04-14T02:20:04.109407+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1806310/0001665124-26-000011.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1806310/0001665124-26-000011.txt","source_event_id":"evt_4d6f93f5e6c4","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"4","fp":"e6bacd0f0a59d0ee","kind":"sec_filing","published_at":"20260413","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["2026-04-13","2026-04-10","2025-06-11","2025-01-02","2034-01-02"],"entities":[{"asset_class":"equity","name":"Taysha Gene Therapies, Inc.","relevance":"high","symbol":"TSHA","type":"issuer"},{"asset_class":"equity","name":"Nagendran Sukumar","relevance":"high","symbol":"","type":"reporting_person"},{"asset_class":"equity","name":"Kamran Alam","relevance":"low","symbol":"","type":"attorney_in_fact"}],"event_type":"listing","information_gaps":["The cleaned text does not clearly state the exact number of shares sold (it shows option-related quantities, but the specific \u201cshares sold\u201d figure is not unambiguously extractable from the provided snippet).","The filing\u2019s \u201cmaterial_items\u201d content is not provided beyond the excerpted footnote text; other Form 4 fields (e.g., total shares beneficially owned after transaction) are not shown in the provided text.","The event_type classification is based on the SEC insider transaction context; the signal itself is a filing discovery delta, not a listing event."],"key_facts":["SEC accession number: 0001665124-26-000011; Form type: 4; filed as of date: 2026-04-13; period of report: 2026-04-10.","Reporting person: Nagendran Sukumar, identified as President and Head of R&D.","Security: Common Stock.","Transaction type includes an option-related sale: \u201cEmployee Stock Option (right to buy)\u201d.","The filing states the transaction was made pursuant to a Rule 10b5-1 trading plan adopted on June 11, 2025.","The price reported is a weighted average price.","Shares were sold in multiple transactions at prices ranging from $4.335 to $4.625 inclusive.","The filing includes a vesting/exercisability schedule: 25% vested and became exercisable on January 2, 2025; remainder vests in 36 equal monthly installments thereafter, subject to continuous service through each vesting date.","Signature: /s/ Kamran Alam, Attorney-in-Fact; dated 2026-04-13."],"numeric_claims":[{"label":"weighted_average_price","value":"$1.71"},{"label":"sale_price_range_min","value":"$4.335"},{"label":"sale_price_range_max","value":"$4.625"},{"label":"trading_plan_adoption_date","value":"2025-06-11"},{"label":"period_of_report","value":"2026-04-10"},{"label":"filed_as_of_date","value":"2026-04-13"},{"label":"option_vesting_initial_date","value":"2025-01-02"},{"label":"monthly_installments_after_initial","value":"36"}],"primary_claim":"Form 4 filed 2026-04-13 by Taysha Gene Therapies, Inc. reports Nagendran Sukumar sold common stock on 2026-04-10 under a Rule 10b5-1 trading plan, with weighted-average price $1.71 and sale prices ranging from $4.335 to $4.625.","relevance_score":0.62,"sentiment":"neutral","source_quality":"high","summary":"Taysha Gene Therapies, Inc. (TSHA) filed a Form 4 on 2026-04-13 reporting insider Nagendran Sukumar\u2019s sale of common stock on 2026-04-10. The filing states the sales were made under a Rule 10b5-1 trading plan and provides weighted-average price and sale price range details.","topics":["SEC Form 4","insider trading","Rule 10b5-1 trading plan","common stock sale","employee stock option","vesting schedule"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 4 \u00b7 Taysha Gene Therapies, Inc. \u00b7 Filed 20260413","ticker":"TSHA","tickers":["TSHA"],"title":"TSHA filed 4","url":"https://www.sec.gov/Archives/edgar/data/1806310/0001665124-26-000011.txt"}}

TEXT NOT NULL

source_ref

TEXT

confidence

REAL (default 0.0

dedupe_key

TEXT

episode_id

TEXT

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

Cancel